Oriza Holdings
VC Fund
Suzhou, China
Oriza Holdings is a Chinese management fund that covers equity, debt financing, and investment since 2007.
- Total investments:
- 224
- Last investment:
- Lead investor:
- 27%
Last updated:
For AI agents: llms.txt
Industries Oriza Holdings invests in
Stages Oriza Holdings invests in
Countries Oriza Holdings invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $4.5M–$30M
- Series A
- $1.5M–$46M
- Series B
- $10M–$100M
Investment Focus
Industry
- Manufacturing 42 (19%)
- Health Care 37 (17%)
- Biotechnology 31 (14%)
- Medical 26 (12%)
- Software 22 (10%)
Stage
- Series A 68 (30%)
- Series B 49 (22%)
- Seed 27 (12%)
- Series C 24 (11%)
- Angel 16 (7%)
Country
- China 176 (79%)
- United States 7 (3%)
- Canada 1 (0%)
- Hong Kong 1 (0%)
- Singapore 1 (0%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Li Huaijie
Senior Partner
|
Senior Partner | Total investments: 1 | Find email | |
Liu chengwei
Chairman & CEO
|
Chairman & CEO | Total investments: 0 | Find email | |
|
Peng Liwen
Investment Director
|
Investment Director | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Pilot Bio is a bio-manufacturing technology research and development company, focusing on bio-manufacturing of major chemical products, bio-process substitution in heavy-polluting industries, etc., providing users with bio-catalytic synthesis processes, enzyme product research and development, production, sales, and downstream companies with enzymeengineering , Technical service outsourcing and production service outsourcing of strain transformation and metabolic engineering. | $67.1M / Venture - Series Unknown / Sep 30, 2026 | ||
| BCI-Sonics is an innovative medtech company developing non-invasive brain-computer interface solutions using advanced transcranial focused ultrasound (tFUS) technology. The company builds a next-generation therapeutic platform enabling precise neuromodulation to treat central nervous system disorders. BCI-Sonics develops low-intensity focusedultrasound technology that non-invasively stimulates deep brain regions with high precision. They combine ultrasound engineering and neuroscience to interface safely and effectively with the human brain without surgery. The company is creating an AI ultrasound brain-computer interface platform for therapeutic neuromodulation applications. | $29.9M / Seed / Sep 22, 2026 | ||
|
Toto Technology
|
Borg Technology is a producer of testing and micromachining tools, with an emphasis on optical and precision optical devices. | $29.8M / Series B / Sep 04, 2026 | |
| Muchuang focuses on the development of reconfigurable programming system chip application systems, chip front-end design, and testing services. Adhering to the product development line of "national secret fusion security, security fusion network, network fusion intelligence", it has two product series oriented towards information securityand network control, and is determined to become a cloud, network, and terminal-oriented reconfigurable security acceleration and Smart network controller chip provider. | Series B / Aug 27, 2026 | ||
|
Dongxi Fusion
|
Dongxi Fusion is an emerging energy technology promotion and technical service provider. The company is dedicated to providing technical services and advancing the adoption and deployment of new energy innovations. | Seed / Aug 25, 2026 | |
|
Ruilian Intelligent Computing
|
Ruilian Zhisuan is an AI computing infrastructure innovator that provides integrated hardware software solutions. Modeled after Google's Jupiter optoelectronic architecture, it features full stack OCS scheduling to replace traditional electronic switches with optical routing. This core technology drastically minimizes network latency andsystem power consumption for advanced AI calculation networks. | $14.8M / Seed / Aug 19, 2026 | |
| Simnova Biotherapeutics is a biopharmaceutical company that focuses on the research and development of cell therapies for cancer treatment. The company's primary therapeutic focus is CAR-based cell therapy for patients with either hematologic malignancies or solid tumors. Simnova Biotherapeutics is known for its innovative approach todeveloping patient-centered therapeutics using current science and technology. The company's lead product is SNC102, a cell therapy product that has been approved for clinical trials. Simnova Biotherapeutics is committed to creating a healthy, inclusive, and harmonious working environment. | $59.3M / Series B / Aug 18, 2026 | ||
|
BuChou Quantum
|
BuChou Quantum’s vision is to create quantum computers with real, practical application value by pursuing deep “software–hardware synergy,” meaning they design quantum hardware and quantum software in tandem so each enhances the other, enabling more powerful, efficient, and usable quantum computing systems. | Series A / Aug 12, 2026 | |
| Delova Biotech specializes in the field of pain treatment. It uses the company's rich R&D experience and special preparation technology platform to improve existing drugs and conduct research and development of improved new analgesics in China and the United States. | $88.6M / Series C / Jul 22, 2026 | ||
| Chuang Technology focuses on the research and application of computer-aided engineering and intelligent industrial design, independently develops the underlying algorithm solver, provides cloud-native intelligent cloud simulation and intelligent design services, and provides high-performance CAE algorithms, intelligent optimization algorithms andindustrial Software research and development and other fields have been at the international forefront. | $14.8M / Series B / Jul 22, 2026 | ||
| See all 224 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Oriza Holdings invest in?
Oriza Holdings invests primarily in Manufacturing, Health Care and Biotechnology startups, most often at Series A and Series B stage. Most of the 224 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Oriza Holdings's check size?
Oriza Holdings typically joins rounds of $4.5M–$30M at Seed, $1.5M–$46M at Series A and $10M–$100M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Oriza Holdings participates in.
How do I contact Oriza Holdings?
Public channels for Oriza Holdings include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Oriza Holdings?
The team at Oriza Holdings includes Li Huaijie (Senior Partner), Liu chengwei (Chairman & CEO) and Peng Liwen (Investment Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
